365 related articles for article (PubMed ID: 12917806)
21. Construction of two Lactococcus lactis expression vectors combining the Gateway and the NIsin Controlled Expression systems.
Douillard FP; Mahony J; Campanacci V; Cambillau C; van Sinderen D
Plasmid; 2011 Sep; 66(3):129-35. PubMed ID: 21807023
[TBL] [Abstract][Full Text] [Related]
22. Surface expression of Helicobacter pylori urease subunit B gene E fragment on Lactococcus lactis by means of the cell wall anchor of Staphylococcus aureus protein A.
Song D; Gu Q
Biotechnol Lett; 2009 Jul; 31(7):985-9. PubMed ID: 19267231
[TBL] [Abstract][Full Text] [Related]
23. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
[TBL] [Abstract][Full Text] [Related]
24. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice.
Perez CA; Eichwald C; Burrone O; Mendoza D
J Appl Microbiol; 2005; 99(5):1158-64. PubMed ID: 16238746
[TBL] [Abstract][Full Text] [Related]
25. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria.
Cortes-Perez NG; Lefèvre F; Corthier G; Adel-Patient K; Langella P; Bermúdez-Humarán LG
Vaccine; 2007 Sep; 25(36):6581-8. PubMed ID: 17675182
[TBL] [Abstract][Full Text] [Related]
26. [Expression of helicobacter pylori alpA gene in lactococcus lactis and its immunogenicity analysis].
Sun ZL; Bi YW; Bai CM; Gao DD; Li ZH; Dai ZX; Li JF; Xu WM
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Mar; 26(3):203-6. PubMed ID: 20230679
[TBL] [Abstract][Full Text] [Related]
27. Incorporation of nisI-mediated nisin immunity improves vector-based nisin-controlled gene expression in lactic acid bacteria.
Oddone GM; Mills DA; Block DE
Plasmid; 2009 May; 61(3):151-8. PubMed ID: 19141301
[TBL] [Abstract][Full Text] [Related]
28. Production of biological active murine IFN-gamma by recombinant Lactococcus lactis.
Bermúdez-Humarán LG; Cortes-Perez NG; L'Haridon R; Langella P
FEMS Microbiol Lett; 2008 Mar; 280(2):144-9. PubMed ID: 18248432
[TBL] [Abstract][Full Text] [Related]
29. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection.
Villena J; Medina M; Raya R; Alvarez S
Can J Microbiol; 2008 Oct; 54(10):845-53. PubMed ID: 18923553
[TBL] [Abstract][Full Text] [Related]
30. Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
Moorthy SA; Yasawardena SG; Ramasamy R
Vaccine; 2009 Aug; 27(36):4947-52. PubMed ID: 19545652
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the local immune response against Giardia lamblia cyst wall protein 2 induced by recombinant Lactococcus lactis and Streptococcus gordonii.
Lee P; Abdul-Wahid A; Faubert GM
Microbes Infect; 2009 Jan; 11(1):20-8. PubMed ID: 18992359
[TBL] [Abstract][Full Text] [Related]
32. Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by
Duarte SOD; Monteiro GA
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573129
[TBL] [Abstract][Full Text] [Related]
33. Nisin-controlled extracellular production of apidaecin in Lactococcus lactis.
Zhou XX; Wang YB; Pan YJ; Li WF
Appl Microbiol Biotechnol; 2008 Apr; 78(6):947-53. PubMed ID: 18286279
[TBL] [Abstract][Full Text] [Related]
34. Cytoplasmic and extracellular expression of pharmaceutical-grade mycobacterial 65-kDa heat shock protein in Lactococcus lactis.
de Azevedo MS; Rocha CS; Electo N; Pontes DS; Molfetta JB; Gonçalves ED; Azevedo V; Silva CL; Miyoshi A
Genet Mol Res; 2012 Apr; 11(2):1146-57. PubMed ID: 22614283
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activity of divercin RV41 produced and secreted by Lactococcus lactis.
Bermúdez-Humarán LG; Rihakova J; Langella P; Demnerova K; Nazef L; Prévost H; Drider D
J Mol Microbiol Biotechnol; 2007; 13(4):259-63. PubMed ID: 17827978
[TBL] [Abstract][Full Text] [Related]
36. Display of heterologous proteins on the surface of Lactococcus lactis using the H and W domain of PrtB from Lactobacillus delburueckii subsp. bulgaricus as an anchoring matrix.
Kim TW; Igimi S; Kajikawa A; Kim HY
J Appl Microbiol; 2008 Jun; 104(6):1636-43. PubMed ID: 18298534
[TBL] [Abstract][Full Text] [Related]
37. Targeting diseases with genetically engineered Lactococcus lactis and its course towards medical translation.
Villatoro-Hernandez J; Montes-de-Oca-Luna R; Kuipers OP
Expert Opin Biol Ther; 2011 Mar; 11(3):261-7. PubMed ID: 21204744
[TBL] [Abstract][Full Text] [Related]
38. Production of biologically active CXC chemokines by Lactococcus lactis: evaluation of its potential as a novel mucosal vaccine adjuvant.
Cortes-Perez NG; da Costa Medina LF; Lefèvre F; Langella P; Bermúdez-Humarán LG
Vaccine; 2008 Oct; 26(46):5778-83. PubMed ID: 18790708
[TBL] [Abstract][Full Text] [Related]
39. Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10.
Huyghebaert N; Vermeire A; Neirynck S; Steidler L; Remaut E; Remon JP
Eur J Pharm Biopharm; 2005 Aug; 60(3):349-59. PubMed ID: 15927456
[TBL] [Abstract][Full Text] [Related]
40. Production, secretion and purification of a correctly folded staphylococcal antigen in Lactococcus lactis.
Samazan F; Rokbi B; Seguin D; Telles F; Gautier V; Richarme G; Chevret D; Varela PF; Velours C; Poquet I
Microb Cell Fact; 2015 Jul; 14():104. PubMed ID: 26178240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
